elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q26752508-ADACF7A4-BF05-4709-A493-92DF2A2433A2
Q26752508-ADACF7A4-BF05-4709-A493-92DF2A2433A2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26752508-ADACF7A4-BF05-4709-A493-92DF2A2433A2
Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged
P2860
Q26752508-ADACF7A4-BF05-4709-A493-92DF2A2433A2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26752508-ADACF7A4-BF05-4709-A493-92DF2A2433A2
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8d2a43250a1ec950347bc70e9fbc2ec32a54c2f2
P2860
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.